- Home
- CNI vs REGN Comparison
CNI vs REGN Comparison
Compare CNI & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNI
- REGN
- Stock Information
- Founded
- CNI 1919
- REGN 1988
- Country
- CNI Canada
- REGN United States
- Employees
- CNI N/A
- REGN N/A
- Industry
- CNI
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- CNI
- REGN Health Care
- Exchange
- CNI Nasdaq
- REGN Nasdaq
- Market Cap
- CNI 60.4B
- REGN 59.5B
- IPO Year
- CNI N/A
- REGN 1991
- Fundamental
- Price
- CNI $96.54
- REGN $589.44
- Analyst Decision
- CNI Buy
- REGN Buy
- Analyst Count
- CNI 14
- REGN 23
- Target Price
- CNI $117.44
- REGN $794.83
- AVG Volume (30 Days)
- CNI 1.7M
- REGN 1.1M
- Earning Date
- CNI 10-31-2025
- REGN 10-28-2025
- Dividend Yield
- CNI 1.87%
- REGN 0.59%
- EPS Growth
- CNI N/A
- REGN 5.03
- EPS
- CNI 5.32
- REGN 39.67
- Revenue
- CNI $12,569,471,933.00
- REGN $14,214,200,000.00
- Revenue This Year
- CNI $2.75
- REGN N/A
- Revenue Next Year
- CNI $4.64
- REGN $4.74
- P/E Ratio
- CNI $17.98
- REGN $15.12
- Revenue Growth
- CNI 0.63
- REGN 5.38
- 52 Week Low
- CNI $91.07
- REGN $476.49
- 52 Week High
- CNI $116.79
- REGN $1,038.81
- Technical
- Relative Strength Index (RSI)
- CNI 60.62
- REGN 54.88
- Support Level
- CNI $93.82
- REGN $555.00
- Resistance Level
- CNI $94.77
- REGN $618.01
- Average True Range (ATR)
- CNI 1.34
- REGN 17.17
- MACD
- CNI 0.43
- REGN 2.16
- Stochastic Oscillator
- CNI 96.59
- REGN 58.90
About CNI Canadian National Railway Company
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2024, CN generated CAD 17 billion in revenue by hauling intermodal containers (22% of consolidated revenue), petroleum and chemicals (20%), grain and fertilizers (20%), forest products (11%), metals and minerals (12%), automotive shipments (5%), and coal (5%). Other items constitute the remaining revenue.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).